GleamWall
中文EN

AQST Aquestive Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%

Returns

ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$7.56M$13.82M$14.45M$13.02M$12.81M$10.00M$8.72M$11.87M
Cost of revenue$3.61M$4.02M$3.47M$5.84M$4.51M$4.56M$3.65M$4.52M
Gross profit$3.95M$9.80M$10.98M$7.18M$8.30M$5.44M$5.07M$7.35M
R&D expense$4.25M$3.96M$4.20M$3.20M$4.53M$4.11M$5.36M$4.92M
SG&A expense$14.17M$14.06M$10.98M$32.82M$15.25M$12.71M$19.07M$16.01M
Operating income-$14.47M-$8.22M-$4.20M-$28.84M-$11.48M-$11.37M-$19.36M-$13.58M
Interest expense$1.84M$2.81M$2.90M$2.78M$2.78M$2.78M$2.78M$2.78M
Pretax income-$16.50M-$22.86M-$8.06M-$31.86M-$15.45M-$13.55M-$22.93M-$17.07M
Income tax$0$0$0$0$0$0$0-$14,000
Net income-$16.50M-$22.86M-$8.06M-$31.86M-$15.45M-$13.55M-$22.93M-$17.05M
EBITDA-$14.31M-$8.09M-$4.09M-$28.71M-$11.34M-$11.23M-$19.23M-$13.43M
EPS (basic)-0.13-0.18-0.07—-0.14-0.14-0.24—
EPS (diluted)-0.13-0.18-0.07—-0.14-0.14-0.24—
Weighted avg. shares (diluted)125.55M124.99M122.61M—110.58M99.33M95.50M—
Balance sheet
Cash & equivalents$90.35M$98.49M$110.73M$121.17M$129.06M$60.54M$68.66M$71.55M
Receivables$5.25M$9.33M$6.87M$17.76M———$7.34M
Inventory$7.31M$7.37M$8.07M$6.17M$7.88M$8.12M$7.20M$6.04M
Current assets$105.83M$118.49M$130.18M$149.27M$151.67M$81.72M$89.17M$88.22M
PP&E, net$4.36M$3.96M$3.84M$3.89M$3.92M$3.86M$3.80M$3.80M
Intangibles———$0$0$0$0$0
Total assets$119.33M$132.10M$141.12M$160.43M$163.56M$93.70M$102.23M$101.42M
Current liabilities$17.30M$16.48M$31.75M$47.61M$25.57M$23.16M$18.30M$18.86M
Short-term debt$33,000$32,000—$9.99M————
Long-term debt$50.76M$50.65M$25.10M$27.52M$45.00M$45.00M$45.00M$32.50M
Total debt$50.79M$50.69M$25.10M$37.51M$45.00M$45.00M$45.00M$32.50M
Total liabilities$190.15M$188.69M$175.18M$194.09M$167.67M$166.29M$163.16M$161.58M
Shareholders' equity-$70.82M-$56.59M-$34.05M-$33.66M-$4.11M-$72.59M-$60.93M-$60.16M
Net debt-$39.56M-$47.80M-$85.64M-$83.66M-$84.06M-$15.54M-$23.66M-$39.05M
Shares outstanding125.69M125.51M124.28M122.04M121.66M99.35M99.32M91.41M
Cash flow statement
Operating cash flow-$7.05M-$9.44M-$14.81M-$8.47M-$12.65M-$7.91M-$23.40M-$6.49M
Capital expenditure$584,000$212,000$52,000$85,000$235,000$107,000$135,000$15,000
Free cash flow-$7.63M-$9.65M-$14.86M-$8.55M-$12.88M-$8.02M-$23.54M-$6.50M
Investing cash flow-$584,000-$212,000-$52,000-$85,000-$235,000-$107,000-$135,000-$15,000
Financing cash flow-$511,000-$2.59M$4.42M$660,000$81.41M-$100,000$20.65M$157,000
Depreciation & amortization$156,000$136,000$113,000$130,000$139,000$140,000$139,000$147,000
Stock-based compensation$2.13M$2.90M$2.32M$1.38M$2.78M$1.88M$1.59M$2.40M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.